GlobeNewswire Inc.··Not SpecifiedARS Pharmaceuticals to Report Q1 2026 Results as Neffy Commercialization Advances
ARS Pharmaceuticals ($SPRY) schedules May 15 earnings call to discuss Q1 2026 results and neffy® nasal spray commercialization progress across U.S., EU, and China markets.
SPRYFDA approvalanaphylaxis